全文获取类型
收费全文 | 6818篇 |
免费 | 474篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 82篇 |
儿科学 | 149篇 |
妇产科学 | 100篇 |
基础医学 | 947篇 |
口腔科学 | 164篇 |
临床医学 | 669篇 |
内科学 | 1679篇 |
皮肤病学 | 91篇 |
神经病学 | 663篇 |
特种医学 | 261篇 |
外科学 | 1027篇 |
综合类 | 59篇 |
一般理论 | 5篇 |
预防医学 | 374篇 |
眼科学 | 131篇 |
药学 | 372篇 |
中国医学 | 8篇 |
肿瘤学 | 535篇 |
出版年
2023年 | 60篇 |
2022年 | 101篇 |
2021年 | 190篇 |
2020年 | 135篇 |
2019年 | 171篇 |
2018年 | 207篇 |
2017年 | 155篇 |
2016年 | 169篇 |
2015年 | 202篇 |
2014年 | 267篇 |
2013年 | 333篇 |
2012年 | 535篇 |
2011年 | 512篇 |
2010年 | 336篇 |
2009年 | 267篇 |
2008年 | 482篇 |
2007年 | 459篇 |
2006年 | 399篇 |
2005年 | 389篇 |
2004年 | 327篇 |
2003年 | 316篇 |
2002年 | 276篇 |
2001年 | 61篇 |
2000年 | 47篇 |
1999年 | 62篇 |
1998年 | 50篇 |
1997年 | 38篇 |
1996年 | 42篇 |
1995年 | 48篇 |
1994年 | 33篇 |
1993年 | 41篇 |
1992年 | 35篇 |
1991年 | 35篇 |
1990年 | 31篇 |
1989年 | 36篇 |
1988年 | 48篇 |
1987年 | 40篇 |
1986年 | 29篇 |
1985年 | 24篇 |
1984年 | 30篇 |
1983年 | 31篇 |
1982年 | 28篇 |
1981年 | 30篇 |
1980年 | 13篇 |
1979年 | 21篇 |
1978年 | 18篇 |
1975年 | 12篇 |
1974年 | 17篇 |
1973年 | 13篇 |
1972年 | 13篇 |
排序方式: 共有7316条查询结果,搜索用时 15 毫秒
61.
Francis X Campion George L Tully Jo-Ann Barrett Paulo Andre Ann Sweeney 《Disease management》2005,8(4):245-252
Disease management for chronic conditions is a call for collaboration among all parties of the health care system. The Caritas Christi Health Care System established a unified American Diabetes Association (ADA) recognized outpatient diabetes self-management education program (DSME) in each of its six hospital communities and has established an Internet data portal with managed care organizations to improve preventive care for thousands of patients with diabetes. This article describes the stepwise process of building the successful Caritas Diabetes Care Program and the central role of the Caritas Diabetes Registry over a 5-year period. 相似文献
62.
Anticoagulant Use in Patients with Chronic Renal Impairment 总被引:3,自引:0,他引:3
Patients with renal failure have an increased risk of both thrombotic and bleeding complications. A number of antithrombotic drugs undergo renal clearance. Therefore, estimation of renal function is necessary when prescribing these drugs to patients with renal dysfunction. Pharmacokinetic and clinical data in patients with chronic renal impairment are limited for several anticoagulants, and adequate administration information is often absent. Dose adjustment of anticoagulants may be indicated when the creatinine clearance falls below 30 mL/min. Unfractionated heparin, argatroban, and vitamin K antagonists generally do not require dose adjustment with renal dysfunction. However, smaller doses of warfarin may be required to achieve a particular target international normalized ratio. Close monitoring of anticoagulation is recommended when argatroban or high doses of unfractionated heparin are administered in patients with severe chronic renal impairment. Low-molecular weight heparins, danaparoid sodium, hirudins, and bivalirudin all undergo renal clearance. Lower doses and closer anticoagulation monitoring may be advisable when these agents are used in patients with chronic renal failure. We recommend that fondaparinux sodium and ximelagatran (not yet licensed) be avoided in the presence of severe renal impairment and be used with caution in patients with moderate renal dysfunction. While acknowledging the lack of pharmacokinetic data, this review provides specific recommendations for the use of anticoagulants in patients with chronic renal impairment. 相似文献
63.
Eleftherios P Mamounas Ann Brown Stewart Anderson Roy Smith Thomas Julian Barbara Miller Harry D Bear Christopher B Caldwell Alonzo P Walker Wendy M Mikkelson Jay S Stauffer Andre Robidoux Heather Theoret Atilla Soran Atilla Sovan Bernard Fisher D Lawrence Wickerham Norman Wolmark 《Journal of clinical oncology》2005,23(12):2694-2702
PURPOSE: Experience with sentinel node biopsy (SNB) after neoadjuvant chemotherapy is limited. We examined the feasibility and accuracy of this procedure within a randomized trial in patients treated with neoadjuvant chemotherapy. PATIENTS AND METHODS: During the conduct of National Surgical Adjuvant Breast and Bowel Project trial B-27, several participating surgeons attempted SNB before the required axillary dissection in 428 patients. All underwent lymphatic mapping and an attempt to identify and remove a sentinel node. Lymphatic mapping was performed with radioactive colloid (14.7%), with lymphazurin blue dye alone (29.9%), or with both (54.7%). RESULTS: Success rate for the identification and removal of a sentinel node was 84.8%. Success rate increased significantly with the use of radioisotope (87.6% to 88.9%) versus with the use of lymphazurin alone (78.1%, P = .03). There were no significant differences in success rate according to clinical tumor size, clinical nodal status, age, or calendar year of random assignment. Of 343 patients who had SNB and axillary dissection, the sentinel nodes were positive in 125 patients and were the only positive nodes in 70 patients (56.0%). Of the 218 patients with negative sentinel nodes, nonsentinel nodes were positive in 15 (false-negative rate, 10.7%; 15 of 140 patients). There were no significant differences in false-negative rate according to clinical patient and tumor characteristics, method of lymphatic mapping, or breast tumor response to chemotherapy. CONCLUSION: These results are comparable to those obtained from multicenter studies evaluating SNB before systemic therapy and suggest that the sentinel node concept is applicable following neoadjuvant chemotherapy. 相似文献
64.
Dirk De Ruysscher Stofferinus Wanders Andre Minken Aniek Lumens Jacqueline Schiffelers Cissie Stultiens Serve Halders Liesbeth Boersma Angela van Baardwijk Tom Verschueren Monique Hochstenbag Gabriel Snoep Brad Wouters Sebastiaan Nijsten S?ren M Bentzen Marinus van Kroonenburgh Michel Ollers Philippe Lambin 《Radiotherapy and oncology》2005,77(1):5-10
BACKGROUND AND PURPOSE: To investigate the effect of radiotherapy planning with a dedicated combined PET-CT simulator of patients with locally advanced non-small cell lung cancer. PATIENTS AND METHODS: Twenty-one patients underwent a pre-treatment simulation on a dedicated hybrid PET-CT-simulator. For each patient, two 3D conformal treatment plans were made: one with a CT based PTV and one with a PET-CT based PTV, both to deliver 60Gy in 30 fractions. The maximum tolerable prescribed radiation dose for CT versus PET-CT PTV was calculated based on constraints for the lung, the oesophagus, and the spinal cord, and the Tumour Control Probability (TCP) was estimated. RESULTS: For the same toxicity levels of the lung, oesophagus and spinal cord, the dose could be increased from 55.2+/-2.0Gy with CT planning to 68.9+/-3.3Gy with the use of PET-CT (P=0.002), with corresponding TCP's of 6.3+/-1.5% for CT and 24.0+/-5.6% for PET-CT planning (P=0.01). CONCLUSIONS: The use of a combined dedicated PET-CT-simulator reduced radiation exposure of the oesophagus and the lung, and thus allowed significant radiation dose escalation whilst respecting all relevant normal tissue constraints. 相似文献
65.
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. 总被引:11,自引:0,他引:11
Andre Goy Anas Younes Peter McLaughlin Barbara Pro Jorge E Romaguera Frederick Hagemeister Luis Fayad Nam H Dang Felipe Samaniego Michael Wang Kristine Broglio Barry Samuels Frederic Gilles Andreas H Sarris Susan Hart Elizabeth Trehu David Schenkein Fernando Cabanillas Alma M Rodriguez 《Journal of clinical oncology》2005,23(4):667-675
PURPOSE: Evaluate efficacy and toxicity of bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. PATIENTS AND METHODS: Patients were stratified, based on preclinical data, into arm A (mantle-cell lymphoma) or arm B (other B-cell lymphomas) without limitation in number of prior therapies. Bortezomib was administered as an intravenous push (1.5 mg/m2) on days 1, 4, 8, and 11 every 21 days for a maximum of six cycles. RESULTS: Sixty patients with a median number of prior therapies of 3.5 (range, one to 12 therapies) were enrolled; 33 patients were in arm A and 27 were in arm B, including 12 diffuse large B-cell lymphomas, five follicular lymphomas (FL), three transformed FLs, four small lymphocytic lymphomas (SLL), two Waldenstrom's macroglobulinemias (WM), and one marginal zone lymphoma. In arm A, 12 of 29 assessable patients responded (six complete responses [CR] and six partial responses [PR]) for an overall response rate (ORR) of 41% (95% CI, 24% to 61%), and a median time to progression not reached yet, with a median follow-up of 9.3 months (range, 1.7 to 24 months). In arm B, four of 21 assessable patients responded (one SLL patient had a CR, one FL patient had a CR unconfirmed, one diffuse large B-cell lymphoma patient had a PR, and one WM patient had a PR) for an ORR of 19% (95% CI, 5% to 42%). Grade 3 toxicity included thrombocytopenia (47%), gastrointestinal (20%), fatigue (13%), neutropenia (10%), and peripheral neuropathy (5%). Grade 4 toxicity occurred in nine patients (15%), and three deaths from progression of disease occurred within 30 days of withdrawal from study. CONCLUSION: Bortezomib showed promising activity in relapsed mantle-cell lymphoma and encouraging results in other B-cell lymphomas. Future studies will explore bortezomib in combination with other cytotoxic or biologic agents. 相似文献
66.
67.
Joel Jayaseelan Ashwath Pazhani Anthony Xavior Michael Jeyapandiarajan Paulchamy Andre Batako Prashantha Kumar Hosamane Guruswamy 《Materials》2022,15(17)
From the aspect of exploring the alternative lightweight composite material for the aerospace launch vehicle external fuel tank structural components, the current research work studies three different grades of Aluminium alloy reinforced with varying graphene weight percentages that are processed through powder metallurgy (P/M) route. The prepared green compacts composite ingots are subjected to microwave processing (Sintering), hot extruded, and solution treated (T6). The developed Nano-graphene reinforced composite is studied further for the strength–microstructural integrity. The nature of the graphene reinforcement and its chemical existence within the composite is further studied, and it is found that hot extruded solution treated (HEST) composite exhibited low levels of carbide (Al4C3) formations, as composites processed by microwaves. Further, the samples of different grades reinforced with varying graphene percentages are subjected to mechanical characterisation tests such as the tensile test and hardness. It is found that 2 wt% graphene reinforced composites exhibited enhanced yield strength and ultimate tensile strength. Microstructural studies and fracture morphology are studied, and it is proven that composite processed via the microwave method has exhibited good ductile behaviour and promising failure mechanisms at higher load levels. 相似文献
68.
Shu-Hua Wang Murgesean V. S. Rajaram Andre Trollip Qian Wu Doris Ayala Danyelle Garza Marielena A. Benavidez Kelsie Fox Genesis P. Aguilln-Durn Erika A. Vargas-Orozco Lou Torres Lianbo Yu S. Rumel Ahmed Megan Aspden Thomas Jackson-Soutter Catherine Coxon Ruth Brignall Blanca I. Restrepo 《Journal of clinical microbiology》2022,60(9)
69.
Lucca R. Policastro Isabela Dolci Andre S. Godoy Jos V. J. Silva Júnior Uriel E. A. Ruiz Igor A. Santos Ana C. G. Jardim Kirandeep Samby Jeremy N. Burrows Timothy N. C. Wells Laura H. V. G. Gil Glaucius Oliva Rafaela S. Fernandes 《Viruses》2022,14(7)
Chikungunya virus (CHIKV) is the causative agent of chikungunya fever, a disabling disease that can cause long-term severe arthritis. Since the last large CHIKV outbreak in 2015, the reemergence of the virus represents a serious public health concern. The morbidity associated with viral infection emphasizes the need for the development of specific anti-CHIKV drugs. Herein, we describe the development and characterization of a CHIKV reporter replicon cell line and its use in replicon-based screenings. We tested 960 compounds from MMV/DNDi Open Box libraries and identified four candidates with interesting antiviral activities, which were confirmed in viral infection assays employing CHIKV-nanoluc and BHK-21 cells. The most noteworthy compound identified was itraconazole (ITZ), an orally available, safe, and cheap antifungal, that showed high selectivity indexes of >312 and >294 in both replicon-based and viral infection assays, respectively. The antiviral activity of this molecule has been described against positive-sense single stranded RNA viruses (+ssRNA) and was related to cholesterol metabolism that could affect the formation of the replication organelles. Although its precise mechanism of action against CHIKV still needs to be elucidated, our results demonstrate that ITZ is a potent inhibitor of the viral replication that could be repurposed as a broad-spectrum antiviral. 相似文献
70.
Anshu Ankolekar Britt van der Heijden Andre Dekker Cheryl Roumen Dirk De Ruysscher Bart Reymen Adriana Berlanga Cary Oberije Rianne Fijten 《Health expectations》2022,25(4):1342
BackgroundLung cancer treatment decisions are typically made among clinical experts in a multidisciplinary tumour board (MTB) based on clinical data and guidelines. The rise of artificial intelligence and cultural shifts towards patient autonomy are changing the nature of clinical decision‐making towards personalized treatments. This can be supported by clinical decision support systems (CDSSs) that generate personalized treatment information as a basis for shared decision‐making (SDM). Little is known about lung cancer patients'' treatment decisions and the potential for SDM supported by CDSSs. The aim of this study is to understand to what extent SDM is done in current practice and what clinicians need to improve it.ObjectiveTo explore (1) the extent to which patient preferences are taken into consideration in non‐small‐cell lung cancer (NSCLC) treatment decisions; (2) clinician perspectives on using CDSSs to support SDM.DesignMixed methods study consisting of a retrospective cohort study on patient deviation from MTB advice and reasons for deviation, qualitative interviews with lung cancer specialists and observations of MTB discussions and patient consultations.Setting and ParticipantsNSCLC patients (N = 257) treated at a single radiotherapy clinic and nine lung cancer specialists from six Dutch clinics.ResultsWe found a 10.9% (n = 28) deviation rate from MTB advice; 50% (n = 14) were due to patient preference, of which 85.7% (n = 12) chose a less intensive treatment than MTB advice. Current MTB recommendations are based on clinician experience, guidelines and patients'' performance status. Most specialists (n = 7) were receptive towards CDSSs but cited barriers, such as lack of trust, lack of validation studies and time. CDSSs were considered valuable during MTB discussions rather than in consultations.ConclusionLung cancer decisions are heavily influenced by clinical guidelines and experience, yet many patients prefer less intensive treatments. CDSSs can support SDM by presenting the harms and benefits of different treatment options rather than giving single treatment advice. External validation of CDSSs should be prioritized.Patient or Public ContributionThis study did not involve patients or the public explicitly; however, the study design was informed by prior interviews with volunteers of a cancer patient advocacy group. The study objectives and data collection were supported by Dutch health care insurer CZ for a project titled ‘My Best Treatment’ that improves patient‐centeredness and the lung cancer patient pathway in the Netherlands. 相似文献